We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.01% | 1,705.00 | 1,705.00 | 1,705.40 | 1,709.60 | 1,699.40 | 1,701.60 | 993,385 | 12:22:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.27 | 70.3B |
TIDMGSK
RNS Number : 0001V
GlaxoSmithKline PLC
22 October 2014
Change to Director's Details - Dr Moncef Slaoui
GlaxoSmithKline plc (the "Company") today confirms that Dr Moncef Slaoui, an Executive Director, is appointed Chairman, Vaccines, with immediate effect.
This appointment will ensure more focused management of the Company's Vaccines business in advance of the completion of the proposed 3 part transaction with Novartis announced earlier this year. Dr Slaoui will continue to provide scientific and technical counsel on pharmaceutical R&D activities to the CEO and Board.
Dr Slaoui was previously Chairman, Global R&D and Vaccines.
V A Whyte
Company Secretary
22 October 2014
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFEWFFEFLSESS
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions